Clinical study on Yanghe Decoction in improving neo-adjuvant chemotherapy efficacy and immune function of breast cancer patients

Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of TCM0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients must be female, aged 18 to 70 years old.
•2. Pathologically confirmed as primary invasive breast cancer by core needle biopsy. All patients had measurable tumor lesions (At least one measurable lesion) before treatment and the clinical staging was IIA ~ IIIC (AJCC 9th edition).
•3. Not received treatment for breast cancer previously.
•4. ECOG Score 0 to 2 ;
•5. The normal range of hematologic examination and blood biochemical examination before treatment.
•6. No serious impairment of cardiac, hepatic and renal functions.
•7. Patients with good compliance.
•8. Signed written informed consent obtained.

•1. Pregnant (serum ß-HCG test) or lactating women;
•2. Distant Metastasis of breast cancer was confirmed;
•3. Patients with evidence of sensory or motor neurone disease;
•4. There are clear signs of cardiovascular disease, severe co-morbidity or active infection, including known HIV infection.
•5. Any previous or concurrent primary malignancy;
•6. Allergic to research drugs or their excipients;
•7. Cannot participant in the study due to any reasons such as language issues, geometrically unable to follow-up, etc.;
•8. Other conditions or diseases that may result in significant risk to the patients as determined by the investigator.

发起方

Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of TCM